Company intelligence / Profile preview

Galapagos NV

Mechelen, N/A, Belgiumglpg.com ↗

Ownership: Public · GLPG
Employees: ~725
Development stage: Commercial

Overview

The company is currently focusing on cell therapy in oncology and has announced plans to separate into two entities. They are seeking partners for their small molecule assets, including the TYK2 inhibitor GLPG3667 which is in Phase 2 for systemic lupus erythematosus and dermatomyositis.

Therapeutic areas: GastroenterologyPulmonologyRheumatologyImmunologyDermatologyOncologyRare Diseases
Modalities: Small MoleculesCell Therapy (CAR-T)Biologics
Industry: Biotech

Drug pipeline

31 assets

filgotinib

30 more assets in the full pipeline.

Request access →

Partnerships

Gilead Sciences

Financials

Market cap: $1.8B
Total revenue: $12.3M
Enterprise value: $-1.1B

Beyond the preview

Go deeper on Galapagos NV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galapagos NV.

Explore the full profile